Redeye leaves its comments on Ortoma following its Q2 2023 report. Ortoma has engaged the market launch in Japan for OTS™ Hip, and the report contained a milestone payment of SEK16.9m leading to a positive EBIT margin.
ANNONS
Redeye leaves its comments on Ortoma following its Q2 2023 report. Ortoma has engaged the market launch in Japan for OTS™ Hip, and the report contained a milestone payment of SEK16.9m leading to a positive EBIT margin.